LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives $97.60 Consensus Price Target from Analysts

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) have received a consensus rating of “Moderate Buy” from the six analysts that are covering the firm, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $97.60.

LMAT has been the topic of a number of research analyst reports. Cantor Fitzgerald lifted their target price on LeMaitre Vascular from $92.00 to $95.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Weiss Ratings restated a “buy (b-)” rating on shares of LeMaitre Vascular in a research report on Saturday, September 27th. Finally, Barrington Research restated an “outperform” rating and issued a $95.00 target price on shares of LeMaitre Vascular in a research report on Tuesday, September 23rd.

LeMaitre Vascular Stock Performance

NASDAQ LMAT opened at $86.79 on Friday. LeMaitre Vascular has a fifty-two week low of $71.42 and a fifty-two week high of $109.58. The company has a debt-to-equity ratio of 0.46, a quick ratio of 11.74 and a current ratio of 13.96. The firm has a market capitalization of $1.96 billion, a P/E ratio of 42.13, a price-to-earnings-growth ratio of 2.25 and a beta of 0.77. The stock’s fifty day moving average is $91.85 and its two-hundred day moving average is $86.32.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 EPS for the quarter, beating analysts’ consensus estimates of $0.57 by $0.03. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%.The company had revenue of $63.15 million for the quarter, compared to the consensus estimate of $62.48 million. During the same quarter in the previous year, the business earned $0.52 earnings per share. The company’s revenue for the quarter was up 15.0% on a year-over-year basis. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. On average, research analysts anticipate that LeMaitre Vascular will post 1.94 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 4th. Stockholders of record on Thursday, August 21st were paid a $0.20 dividend. The ex-dividend date of this dividend was Thursday, August 21st. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.9%. LeMaitre Vascular’s payout ratio is presently 38.83%.

Insider Transactions at LeMaitre Vascular

In other news, Director David B. Roberts sold 10,815 shares of LeMaitre Vascular stock in a transaction on Monday, August 11th. The stock was sold at an average price of $92.39, for a total value of $999,197.85. Following the completion of the sale, the director directly owned 17,976 shares of the company’s stock, valued at approximately $1,660,802.64. The trade was a 37.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director John A. Roush sold 6,561 shares of LeMaitre Vascular stock in a transaction on Monday, August 11th. The shares were sold at an average price of $92.55, for a total value of $607,220.55. Following the completion of the sale, the director directly owned 2,916 shares of the company’s stock, valued at $269,875.80. The trade was a 69.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 120,815 shares of company stock valued at $11,280,206. Corporate insiders own 9.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of LMAT. GAMMA Investing LLC boosted its holdings in LeMaitre Vascular by 7,486.5% in the first quarter. GAMMA Investing LLC now owns 53,864 shares of the medical instruments supplier’s stock valued at $4,519,000 after purchasing an additional 53,154 shares during the period. NBC Securities Inc. purchased a new position in LeMaitre Vascular in the first quarter valued at $36,000. Vest Financial LLC purchased a new position in LeMaitre Vascular in the first quarter valued at $1,470,000. Compass Planning Associates Inc boosted its holdings in LeMaitre Vascular by 91.4% in the first quarter. Compass Planning Associates Inc now owns 11,776 shares of the medical instruments supplier’s stock valued at $988,000 after purchasing an additional 5,623 shares during the period. Finally, Wesbanco Bank Inc. purchased a new position in LeMaitre Vascular in the first quarter valued at $470,000. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.